Karl Patterson, PhD
Principal Health Economist
Karl originally joined BresMed as part of the Editorial team in February 2015, after obtaining a PhD in molecular oncology, studying chemotherapies and DNA damage in bladder cancer. Karl then moved to the Health Economics Analysis team, where he now leads the designing, building and reviewing of economic models (ranging from early feasibility analyses to global models) and health technology assessment (HTA) submissions for the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the National Centre for Pharmacoeconomics (NCPE).
Karl has experience in a number of different oncology indications, including urothelial, colorectal, liver, melanoma, myeloma, lung and renal cancer, and has supported reimbursement efforts in multiple markets.